Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1962 1
1964 1
1967 2
1968 3
1969 3
1970 4
1971 3
1973 2
1974 2
1975 2
1976 2
1977 5
1978 3
1979 1
1980 7
1981 4
1982 2
1983 2
1984 4
1985 4
1986 8
1987 5
1988 4
1989 8
1990 4
1991 8
1992 8
1993 4
1994 4
1995 8
1996 3
1997 8
1998 3
1999 6
2000 10
2001 11
2002 3
2003 5
2004 6
2005 4
2006 8
2007 1
2008 7
2009 2
2010 6
2011 3
2012 3
2013 2
2014 3
2015 4
2016 1
2017 7
2018 5
2019 9
2020 11
2021 7
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Results by year

Filters applied: . Clear all
Page 1
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. DiNardo CD, et al. Among authors: koller e. N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971. N Engl J Med. 2020. PMID: 32786187 Clinical Trial.
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.
Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF. Jaramillo S, et al. Among authors: koller e. Blood Cancer J. 2017 May 26;7(5):e564. doi: 10.1038/bcj.2017.45. Blood Cancer J. 2017. PMID: 28548643 Free PMC article. Clinical Trial.
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
Ivanov D, Milosevic Feenstra JD, Sadovnik I, Herrmann H, Peter B, Willmann M, Greiner G, Slavnitsch K, Hadzijusufovic E, Rülicke T, Dahlhoff M, Hoermann G, Machherndl-Spandl S, Eisenwort G, Fillitz M, Sliwa T, Krauth MT, Bettelheim P, Sperr WR, Koller E, Pfeilstöcker M, Gisslinger H, Keil F, Kralovics R, Valent P. Ivanov D, et al. Among authors: koller e. Am J Hematol. 2023 May;98(5):770-783. doi: 10.1002/ajh.26889. Epub 2023 Mar 9. Am J Hematol. 2023. PMID: 36814396 Free PMC article.
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn MWM, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, Döhner K, Ganser A; German–Austrian AML Study Group. Döhner H, et al. Among authors: koller e. Lancet Haematol. 2023 Jul;10(7):e495-e509. doi: 10.1016/S2352-3026(23)00089-3. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187198 Clinical Trial.
Olanzapine-associated diabetes mellitus.
Koller EA, Doraiswamy PM. Koller EA, et al. Pharmacotherapy. 2002 Jul;22(7):841-52. doi: 10.1592/phco.22.11.841.33629. Pharmacotherapy. 2002. PMID: 12126218 Review.
Translating pharmacology models effectively to predict therapeutic benefit.
Dudal S, Bissantz C, Caruso A, David-Pierson P, Driessen W, Koller E, Krippendorff BF, Lechmann M, Olivares-Morales A, Paehler A, Rynn C, Türck D, Van De Vyver A, Wang K, Winther L. Dudal S, et al. Among authors: koller e. Drug Discov Today. 2022 Jun;27(6):1604-1621. doi: 10.1016/j.drudis.2022.03.009. Epub 2022 Mar 15. Drug Discov Today. 2022. PMID: 35304340 Free article. Review.
Diligent Design Enables Antibody-ASO Conjugates with Optimal Pharmacokinetic Properties.
Sela T, Mansø M, Siegel M, Marban-Doran C, Ducret A, Niewöhner J, Ravn J, Martin RE, Sommer A, Lohmann S, Krippendorff BF, Ladefoged M, Indlekofer A, Quaiser T, Bueddefeld F, Koller E, Mohamed MY, Oelschlaegel T, Gothelf KV, Hofer K, Schumacher FF. Sela T, et al. Among authors: koller e. Bioconjug Chem. 2023 Nov 15;34(11):2096-2111. doi: 10.1021/acs.bioconjchem.3c00393. Epub 2023 Nov 2. Bioconjug Chem. 2023. PMID: 37916986
Clozapine-associated diabetes.
Koller E, Schneider B, Bennett K, Dubitsky G. Koller E, et al. Am J Med. 2001 Dec 15;111(9):716-23. doi: 10.1016/s0002-9343(01)01000-2. Am J Med. 2001. PMID: 11747852
Iron metabolism and iron supplementation in cancer patients.
Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K, Gisslinger H, Koller E, Kopetzky G, Lang A, Rumpold H, Steurer M, Kamali H, Link H. Ludwig H, et al. Among authors: koller e. Wien Klin Wochenschr. 2015 Dec;127(23-24):907-19. doi: 10.1007/s00508-015-0842-3. Epub 2015 Sep 15. Wien Klin Wochenschr. 2015. PMID: 26373748 Free PMC article. Review.
259 results